Cover Image
市場調查報告書

降膽固醇藥世界市場預測 2017-2027:他汀類與固定劑量複方藥、膽固醇吸收抑制劑、離子交換樹脂、貝特類、PCSK9抑制劑、新藥

Global Cholesterol-Lowering Drugs Market 2017-2027: Statins and Fixed-Dose Combinations, Cholesterol Absorption Inhibitors, Ion Exchange Resins, Fibrates, PCSK9 Inhibitors, Novel Drugs

出版商 Visiongain Ltd 商品編碼 344395
出版日期 內容資訊 英文 181 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
降膽固醇藥世界市場預測 2017-2027:他汀類與固定劑量複方藥、膽固醇吸收抑制劑、離子交換樹脂、貝特類、PCSK9抑制劑、新藥 Global Cholesterol-Lowering Drugs Market 2017-2027: Statins and Fixed-Dose Combinations, Cholesterol Absorption Inhibitors, Ion Exchange Resins, Fibrates, PCSK9 Inhibitors, Novel Drugs
出版日期: 2017年08月25日 內容資訊: 英文 181 Pages
簡介

降膽固醇藥世界市場調查期間前期預計為4.9%年複合成長率(CAGR)、2017年達192億美元規模。

本報告針對降膽固醇藥世界市場調查、提供產業與膽固醇疾病概要、市場分類與地區分類市場預測、收益預測、主要企業評價、市場成長各種影響因素。

第1章 調查概要

第2章 降膽固醇藥:概要

  • 製藥產業概略
  • 膽固醇:重要脂肪成分
  • 膽固醇作用
  • 新陳代謝與膽固醇循環
  • 心疾病膽固醇影響
  • 心疾病膽固醇影響:一般說法
  • 心疾病膽固醇影響:討論
  • HDL膽固醇
  • 高膽固醇血症原因
  • 高膽固醇血症治療
    • 英國高膽固醇血症治療指南
    • 美國高膽固醇血症治療指南
    • 生活方式變化
    • 降膽固醇藥分類
    • 其他治療法

第3章 降膽固醇藥市場預測

  • 降膽固醇藥世界市場:種類分類
  • 降膽固醇藥市場:他汀類與固定劑量複方藥
  • 降膽固醇藥市場:吸收抑制劑、離子交換樹脂、貝特類系藥與其他治療藥
  • PCSK9抑制劑
  • 降膽固醇藥世界市場:新藥

第4章 降膽固醇藥世界市場:種類分類市場預測

  • 市場概要
  • 他汀類與固定劑量複方藥市場預測
  • 吸收抑制劑、離子交換樹脂、貝特類系藥與其他治療藥市場預測
  • PCSK9抑制劑市場預測
  • 新藥市場預測

第5章 他汀類與固定劑量複方藥市場預測:種類分類

  • 市場概要
  • Crestor
  • Lipitor
  • Livalo
  • Lescol/Lascol XL
  • Zocor
  • Vytorin
  • Caduet
  • 其他

第6章 吸收抑制劑、離子交換樹脂、貝特類系治療藥市場預測:產品分類

  • 市場概要
  • Zetia
  • Welchol
  • Tricor
  • 其他

第7章 PCSK抑制劑市場預測:產品分類

  • 市場概要
  • Praulent
  • Repatha
  • EN316
  • 其他

第8章 新降膽固醇藥市場預測:產品分類

  • 市場概要
  • Juxtapid
  • Kynamro
  • MK-0859
  • 其他

第9章 地區分析

  • 降膽固醇藥世界市場:地區分類
  • 北美
  • 南美
  • 歐洲
  • 亞太地區
  • 其他地區

第10章 降膽固醇藥世界市場:定性分析

  • SWOT分析
  • 五力分析

第11章 主要企業

  • AstraZeneca Plc
  • Merck & Co. Inc.
  • Pfizer Inc.
  • 興和
  • 第一三共
  • AbbVie Inc.
  • Novartis AG
  • Sanofi S.A.
  • Amgen Inc.
  • BRISTOL-MYERS SQUIBB

第12章 結論

  • 主要地區市場
  • 主要市場分類
  • 降膽固醇藥世界市場:促進因素

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: PHA0229

The global cholesterol-lowering drugs market is expected to grow at a CAGR of 4.9% in the first half of the forecast period. The market is estimated at $19.2bn in 2017. In the Statins and Fixed-Dose Combinations segment, Crestor was on the lead in 2016 and held a share of 26.7%.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 181-page report you will receive 89 tables and 107 figures - all unavailable elsewhere.

The 181-page report provides clear detailed insight into the global cholesterol-lowering drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope

  • Global Cholesterol-Lowering Drugs market forecasts from 2017-2027
  • This report also breaks down the revenue forecast from 2017-2027 for the global cholesterol-lowering drugs market by its main segments:
  • Statins and Fixed-Dose Combinations
  • Cholesterol Absorption Inhibitors, Ion Exchange Resins, Fibrates
  • PCSK9 Inhibitors
  • Novel Cholesterol-Lowering Drugs
  • This report provides revenue forecast from 2017-2027 for the leading drugs under the Statins and Fixed-Dose Combination segment:
  • Crestor
  • Lipitor
  • Livalo
  • Lescol/Lescol XL
  • Zocor
  • Vytorin
  • Caduet
  • Others
  • This report provides revenue forecast from 2017-2027 for the leading drugs under the Cholesterol Absorption Inhibitors, Ion Exchange Resins, Fibrates segment:
  • Zetia
  • Welchol
  • Tricor
  • Others
  • This report provides revenue forecast from 2017-2027 for the leading drugs under the PCSK9 Inhibitor segment:
  • Praluent
  • Repatha
  • RN316
  • Others
  • This report provides revenue forecast from 2017-2027 for the leading drugs under the novel cholesterol-lowering drugs segment:
  • Juxtapid
  • Kynamro
  • MK-0859
  • Others
  • This report provides individual revenue forecasts to 2027 for these regional and national markets:
  • North America: the US, Canada, Mexico
  • South America: Brazil, Argentina, Paraguay, Bolivia, Rest of South America
  • Europe: Germany, France, the UK, Spain, Italy, Rest of Europe
  • Asia-Pacific: Japan, China, India, Australia, Thailand, Rest of APAC
  • RoW: Middle East, Africa, Other Countries

image1

  • Our study provides SWOT and Porter's Five Forces analysis that influence the global cholesterol-lowering drugs market
  • Our study discusses the selected leading companies that are the major players in the cholesterol-lowering drugs market:
  • AstraZeneca
  • Merck & Co
  • Pfizer
  • Kowa Company
  • Daiichi Sankyo
  • AbbVie
  • Novartis
  • Sanofi
  • Amgen
  • Bristol-Myers Squibb (BMS)

Visiongain's study is intended for anyone requiring commercial analyses for the global cholesterol-lowering drugs market. You find data, trends and predictions.

Table of Contents

1. Report Overview

  • 1.1 Global Cholesterol-Lowering Drugs Market Overview
  • 1.2 Research Methodology
    • 1.2.1 Primary Research
    • 1.2.2 Secondary Research
    • 1.2.3 Market Evaluation & Forecasting Methodology
  • 1.3 Global Cholesterol-Lowering Drugs Market Segmentation
  • 1.4 Why You Should Read This Report
  • 1.5 How this report delivers?
  • 1.6 Key Questions Answered by This Analytical Report
  • 1.7 Frequently Asked Questions (FAQ)
  • 1.8 Who is This Report For?
  • 1.9 Associated Visiongain Reports
  • 1.10 About Visiongain

2. Introduction to Cholesterol-Lowering Drugs

  • 2.1 The Pharmaceutical Industry: A Brief Overview
  • 2.2 Cholesterol: An Essential Lipid
  • 2.3 The Functions of Cholesterol
  • 2.4 Metabolism and Circulation of Cholesterol
  • 2.5 The Role of Cholesterol in Heart Disease
  • 2.6 The Role of Cholesterol in Heart Disease: The Orthodoxy
    • 2.6.1 The IMPROVE-IT Study
  • 2.7 The Role of Cholesterol in Heart Disease: The Controversy
  • 2.8 Raising HDL Cholesterol: A Worthwhile Aim?
  • 2.9 Causes of Hypercholesterolaemia
    • 2.9.1 Atherosclerosis
    • 2.9.2 Dyslipidaemia, Hyperlipidaemia and Hyperlipoproteinaemia
    • 2.9.3 Familial Hypercholesterolaemia
  • 2.10 Treatment of Hypercholesterolaemia
    • 2.10.1 UK Treatment Guidelines for Hypercholesterolaemia
    • 2.10.2 US Treatment Guidelines for Hypercholesterolaemia
    • 2.10.3 Lifestyle Changes
    • 2.10.4 Drugs to Lower Cholesterol
    • 2.10.5 Other Therapeutic Approaches
      • 2.10.5.1 Partial Ileal Bypass: An Outdated Surgical Treatment
      • 2.10.5.2 LDL Apheresis: Directly Removing Cholesterol
      • 2.10.5.3 Liver Transplantation for Familial Hypercholesterolaemia

3. Global Cholesterol-Lowering Drugs Market Forecast 2017 - 2027

  • 3.1 Global Cholesterol-Lowering Drugs Market by Type, 2017-2027
  • 3.2 Cholesterol-Lowering Drugs Market: Statins and Fixed Dose Combination, 2017-2027
  • 3.3 Cholesterol-Lowering Drugs Market: Absorption Inhibitors, Ion Exchange Resins, Fibrates and Other Drugs, 2017-2027
  • 3.4 Cholesterol-Lowering Drugs Market: PCSK9 Inhibitors, 2017-2027
  • 3.5 Cholesterol-Lowering Drugs Market: Novel Drugs, 2017-2027

4. Global Cholesterol-Lowering Drugs Market Segments, by Type: Market Forecast 2017 - 2027

  • 4.1 Overview
  • 4.2 Statins and Fixed-Dose Combinations Market Forecast 2017 - 2027
  • 4.3 Absorption Inhibitors, Ion Exchange Resins, Fibrates and Other Market Forecast 2017 - 2027
  • 4.4 PCSK9 Inhibitors Market Forecast 2017 - 2027
  • 4.5 Novel Cholesterol-Lowering Drugs Market Forecast 2017 - 2027

5. Global Statins and Fixed-Dose Combinations for Cholesterol-Lowering Drugs Market by Product: Market Forecast 2017 - 2027

  • 5.1 Overview
  • 5.2 Crestor Market Forecast 2017 - 2027
  • 5.3 Lipitor Market Forecast 2017 - 2027
  • 5.4 Livalo Market Forecast 2017 - 2027
  • 5.5 Lescol /Lescol XL Market Forecast 2017 - 2027
  • 5.6 Zocor Market Forecast 2017 - 2027
  • 5.7 Vytorin Market Forecast 2017 - 2027
  • 5.8 Caduet Market Forecast 2017 - 2027
  • 5.9 Others Market Forecast 2017 - 2027

6. Global Absorption Inhibitors, Ion Exchange Resins, Fibrates and Other Drugs Market by Product: Market Forecast 2017 to 2027

  • 6.1 Overview
  • 6.2 Zetia Market Forecast 2017 - 2027
  • 6.3 Welchol Market Forecast 2017 - 2027
  • 6.4 Tricor Market Forecast 2017 - 2027
  • 6.5 Others Market Forecast 2017 - 2027

7. Global PCSK9 Inhibitors for Cholesterol-Lowering Drug Market by Product: Market Forecast 2017 - 2027

  • 7.1 Overview
  • 7.2 Praluent Market Forecast 2017 - 2027
  • 7.3 Repatha Market Forecast 2017 - 2027
  • 7.4 RN316 Market Forecast 2017 - 2027
  • 7.5 Others Market Forecast 2017 - 2027

8. Global Novel Cholesterol-Lowering Market Forecast by Product: Market Forecast 2017 - 2027

  • 8.1 Overview
  • 8.2 Juxtapid Market Forecast 2017 - 2027
  • 8.3 Kynamro Market Forecast 2017 - 2027
  • 8.4 MK-0859 Market Forecast 2017 - 2027
  • 8.5 Other Market Forecast 2017 - 2027

9. Regional and National Cholesterol-Lowering Drugs Market Forecasts 2017 - 2027

  • 9.1 Regional Cholesterol-Lowering Drugs Market Forecast 2017-2027
  • 9.2 North American Cholesterol-Lowering Drugs Market Forecast 2017-2027
    • 9.2.1 USA Cholesterol-Lowering Drugs Market Forecast 2017-2027
    • 9.2.2 Canada Cholesterol-Lowering Drugs Market Forecast 2017-2027
    • 9.2.3 Mexico Cholesterol-Lowering Drugs Market Forecast 2017-2027
  • 9.3 South America Cholesterol-Lowering Drugs Market Forecast 2017-2027
    • 9.3.1 Brazil Cholesterol-Lowering Drugs Market Forecast 2017-2027
    • 9.3.2 Argentina Cholesterol-Lowering Drugs Market Forecast 2017-2027
    • 9.3.3 Paraguay Cholesterol-Lowering Drugs Market Forecast 2017-2027
    • 9.3.4 Bolivia Cholesterol-Lowering Drugs Market Forecast 2017-2027
    • 9.3.5 Rest of South America Cholesterol-Lowering Drugs Market Forecast 2017-2027
  • 9.4 European Cholesterol-Lowering Drugs Market Forecast 2017-2027
    • 9.4.1 France Cholesterol-Lowering Drugs Market Forecast 2017-2027
    • 9.4.2 Germany Cholesterol-Lowering Drugs Market Forecast 2017-2027
    • 9.4.3 UK Cholesterol-Lowering Drugs Market Forecast 2017-2027
    • 9.4.4 Spain Cholesterol-Lowering Drugs Market Forecast 2017-2027
    • 9.4.5 Italy Cholesterol-Lowering Drugs Market Forecast 2017-2027
    • 9.4.6 Rest of Europe Cholesterol-Lowering Drugs Market Forecast 2017-2027
  • 9.5 Asia-Pacific Cholesterol-Lowering Drugs Market Forecast 2017-2027
    • 9.5.1 China Cholesterol-Lowering Drug Market Forecast 2017-2027
    • 9.5.2 Japan Cholesterol-Lowering Drug Market Forecast 2017-2027
    • 9.5.3 India Cholesterol-Lowering Drug Market Forecast 2017-2027
    • 9.5.4 Australia Cholesterol-Lowering Drug Market Forecast 2017-2027
    • 9.5.5 Thailand Cholesterol-Lowering Drug Market Forecast 2017-2027
    • 9.5.6 Rest of APAC Cholesterol-Lowering Drug Market Forecast 2017-2027
  • 9.6 Rest of World Cholesterol-Lowering Drug Market Forecast 2017-2027
    • 9.6.1 Middle East Cholesterol-Lowering Drug Market Forecast 2017-2027
    • 9.6.2 Africa Cholesterol-Lowering Drug Market Forecast 2017-2027
    • 9.6.3 Other countries Cholesterol-Lowering Drug Market Forecast 2017-2027

10. Cholesterol-Lowering Drug Market, Qualitative Analysis, 2017-2027

  • 10.1 Strengths
    • 10.1.1 Strong Pipeline
    • 10.1.2 High Profile Encouraging Healthcare Provision
  • 10.2 Weaknesses
    • 10.2.1 Increasing Generic Penetration
    • 10.2.2 Approved Indications Limited for New Products
  • 10.3 Opportunities
    • 10.3.1 Increasing Prevalence in Emerging Markets
    • 10.3.2 Possible Additional Indications
  • 10.4 Threats
    • 10.4.1 Patent Expiry
    • 10.4.2 Cost-Containment
  • 10.5 Porter's Five Forces Analysis of the Cholesterol-Lowering Drugs Market
    • 10.5.1 Rivalry among Competitors [High]
    • 10.5.2 Threat of New Entrants [Medium]
    • 10.5.3 Power of Suppliers [Low]
    • 10.5.4 Power of Buyers [Medium]
    • 10.5.5 Threat of Substitutes [High]

11. Leading Companies in the Cholesterol Lowering Drugs Market

  • 11.1 AstraZeneca Plc
    • 11.1.1 AstraZeneca Plc: Company Overview
    • 11.1.2 AstraZeneca Plc: Product Portfolio
    • 11.1.3 AstraZeneca Plc: Recent Developments
  • 11.2 Merck & Co. Inc.
    • 11.2.1 Merck & Co. Inc.: Company Overview
    • 11.2.2 Merck & co. Inc.: Product Portfolio
    • 11.2.3 Merck & Co. Inc.: Recent Developments
  • 11.3 Pfizer Inc.
    • 11.3.1 Pfizer Inc.: Company Overview
    • 11.3.2 Pfizer Inc.: Product Portfolio
    • 11.3.3 Pfizer Inc.: Recent Developments
  • 11.4 Kowa Company, Ltd.
    • 11.4.1 Kowa Company, Ltd.: Company Overview
    • 11.4.2 Kowa Company, Ltd.: Product Portfolio
    • 11.4.3 Kowa Company, Ltd.: Recent Developments
  • 11.5 Daiichi Sankyo Co., Ltd.
    • 11.5.1 Daiichi Sankyo Co., Ltd.: Company Overview
  • 11.6 AbbVie Inc.
    • 11.6.1 AbbVie Inc.: Company Overview
    • 11.6.2 AbbVie Inc.: Product Portfolio
  • 11.7 Novartis AG
    • 11.7.1 Novartis AG: Company Overview
    • 11.7.2 Novartis AG: Product Portfolio
    • 11.7.3 Novartis AG: Recent Developments
  • 11.8 Sanofi S.A.
    • 11.8.1 Sanofi S.A.: Company Overview
    • 11.8.2 Sanofi S.A.: Product Portfolio
    • 11.8.3 Sanofi S.A: Recent Developments
  • 11.9 Amgen Inc.
    • 11.9.1 Amgen Inc.: Company Overview
    • 11.9.2 Amgen Inc.: Product Portfolio
    • 11.9.3 Amgen Inc.: Recent Developments
  • 11.10 BRISTOL-MYERS SQUIBB
    • 11.10.1 Bristol-Myers Squibb: Company Overview
    • 11.10.2 Bristol-Myers Squibb: Product Portfolio

12. Conclusions

  • 12.1 Leading Regional Markets: 2017-2027
  • 12.2 Current Leading Segments: 2017-2027
  • 12.3 World Cholesterol-Lowering Drugs Market: Market Driving Factors

Appendices

  • Associated Visiongain Reports
  • Visiongain Report Sales Order Form
  • About Visiongain
  • Visiongain report evaluation form

List of Tables

  • Table 3.1. Global Cholesterol-Lowering Drugs Market Forecast ($m, AGR%, CAGR%) 2017-2027
  • Table 4.1. Global Cholesterol-Lowering Drugs Market Segments, by Type ($m, AGR%, CAGR%) 2017-2027
  • Table 4.2. Global Statins and Fixed-Dose Combinations for Cholesterol-Lowering Drugs Market Forecast, ($m, AGR%, CAGR%) 2017-2027
  • Table 4.3. Global Statins and Fixed-Dose Combinations for Cholesterol-Lowering Drugs Market Forecast, by Geography, ($m, AGR%, CAGR%) 2017-2027
  • Table 4.4. Global Absorption Inhibitors, Ion Exchange Resins, Fibrates and Other for Cholesterol-Lowering Drugs Market Forecast, ($m, AGR%, CAGR%) 2017-2027
  • Table 4.5. Global Absorption Inhibitors, Ion Exchange Resins, Fibrates and Other for Cholesterol-Lowering Drugs Market Forecast, by Geography, ($m, AGR%, CAGR%) 2017-2027
  • Table 4.6. Global PCSK9 Inhibitors for Cholesterol-Lowering Drugs Market Forecast, ($m, AGR%, CAGR%) 2017-2027
  • Table 4.7. Global PCSK9 Inhibitors for Cholesterol-Lowering Drugs Market Forecast, by Geography, ($m, AGR%, CAGR%) 2017-2027
  • Table 4.8. Global Novel Cholesterol-Lowering Drugs for Cholesterol-Lowering Drugs Market Forecast, ($m, AGR%, CAGR%) 2017-2027
  • Table 4.9. Global Novel Cholesterol-Lowering Drugs for Cholesterol-Lowering Drugs Market Forecast, by Geography, ($m, AGR%, CAGR%) 2017-2027
  • Table 5.1. Global Statins and Fixed-Dose Combinations Market by Product($m, AGR%, CAGR%) 2017-2027
  • Table 5.2. Global Crestor Market Forecast ($m, AGR%, CAGR%) 2017-2027
  • Table 5.3. Global Lipitor Market Forecast ($m, AGR%, CAGR%) 2017-2027
  • Table 5.4. Global Livalo Market Forecast ($m, AGR%, CAGR%) 2017-2027
  • Table 5.5. Global Lescol /Lescol XL Market Forecast ($m, AGR%, CAGR%) 2017-2027
  • Table 5.6. Global Zocor Market Forecast ($m, AGR%, CAGR%) 2017-2027
  • Table 5.7. Global Vytorin Market Forecast ($m, AGR%, CAGR%) 2017-2027
  • Table 5.8. Global Caduet Market Forecast ($m, AGR%, CAGR%) 2017-2027
  • Table 5.9. Global Others Market of Statins and Fixed-Dose Combinations Segment ($m, AGR%, CAGR%) 2017-2027
  • Table 6.1. Global Absorption Inhibitors, Ion Exchange Resins, Fibrates and Other Drugs Market by Product ($m, AGR%, CAGR%) 2017-2027
  • Table 6.2. Global Zetia Market Forecast ($m, AGR%, CAGR%) 2017-2027
  • Table 6.3. Global Welchol Market Forecast ($m, AGR%, CAGR%) 2017-2027
  • Table 6.4. Global Tricor Market Forecast($m, AGR%, CAGR%) 2017-2027
  • Table 6.5. Global Others Market of the Absorption Inhibitors, Ion Exchange Resins, Fibrates and Other Drugs Segment ($m, AGR%, CAGR%) 2017-2027
  • Table 7.1. Global PCSK9 Inhibitors Market by Product ($m, AGR%, CAGR%) 2017-2027
  • Table 7.2. Global Praluent Market Forecast, ($m, AGR%, CAGR%) 2017-2027
  • Table 7.3. Global Repatha Market Forecast, ($m, AGR%, CAGR%) 2017-2027
  • Table 7.4. Global RN316 Market Forecast ($m, AGR%, CAGR%) 2017-2027
  • Table 7.5. Global Others Market of the PCSK9 Inhibitors Segment ($m, AGR%, CAGR%) 2017-2027
  • Table 8.1. Global Novel Cholesterol-Lowering Drugs by Product ($m, AGR%, CAGR%) 2017-2027
  • Table 8.2. Global Juxtapid Market Forecast, ($m, AGR%, CAGR%) 2017-2027
  • Table 8.3. Global Kynamro Market Forecast, ($m, AGR%, CAGR%) 2017-2027
  • Table 8.4. Global MK-089 Market Forecast, ($m, AGR%, CAGR%) 2017-2027
  • Table 8.5. Global Other Drugs Market of the Novel Cholesterol-Lowering Drugs Segment, ($m, AGR%, CAGR%) 2017-2027
  • Table 9.1. Global Cholesterol-Lowering Drugs Market Forecast by Geography, ($m, AGR%, CAGR%) 2017-2027
  • Table 9.2. North America Cholesterol-Lowering Drugs Market Forecast by Country, ($m, AGR%, CAGR%) 2017-2027
  • Table 9.3. USA Cholesterol-Lowering Drugs Market Forecast, ($m, AGR%, CAGR%) 2017-2027
  • Table 9.4. Canada Cholesterol-Lowering Drugs Market Forecast, ($m, AGR%, CAGR%) 2017-2027
  • Table 9.5. Mexico Cholesterol-Lowering Drugs Market Forecast, ($m, AGR%, CAGR%) 2017-2027
  • Table 9.6. South America Cholesterol-Lowering Drugs Market Forecast, by Country ($m, AGR%, CAGR%) 2017-2027
  • Table 9.7. Brazil Cholesterol-Lowering Drugs Market Forecast, ($m, AGR%, CAGR%) 2017-2027
  • Table 9.8. Argentina Cholesterol-Lowering Drugs Market Forecast, ($m, AGR%, CAGR%) 2017-2027
  • Table 9.9. Paraguay Cholesterol-Lowering Drugs Market Forecast, ($m, AGR%, CAGR%) 2017-2027
  • Table 9.10. Bolivia Cholesterol-Lowering Drugs Market Forecast, ($m, AGR%, CAGR%) 2017-2027
  • Table 9.11. Rest of South America Cholesterol-Lowering Drugs Market Forecast, ($m, AGR%, CAGR%) 2017-2027
  • Table 9.12. European Cholesterol-Lowering Drugs Market Forecast by Country ($m, AGR%, CAGR%) 2017-2027
  • Table 9.13. France Cholesterol-Lowering Drugs Market Forecast, ($m, AGR%, CAGR%) 2017-2027
  • Table 9.14. Germany Cholesterol-Lowering Drugs Market Forecast, ($m, AGR%, CAGR%) 2017-2027
  • Table 9.15. UK Cholesterol-Lowering Drugs Market Forecast, ($m, AGR%, CAGR%) 2017-2027
  • Table 9.16. Spain Cholesterol-Lowering Drugs Market Forecast, ($m, AGR%, CAGR%) 2017-2027
  • Table 9.17. Italy Cholesterol-Lowering Drugs Market Forecast, ($m, AGR%, CAGR%) 2017-2027
  • Table 9.18. Rest of European Cholesterol-Lowering Drugs Market Forecast, ($m, AGR%, CAGR%) 2017-2027
  • Table 9.19. Asia-Pacific Cholesterol-Lowering Drug Market Forecast by Country, ($m, AGR%, CAGR%) 2017-2027
  • Table 9.20. China Cholesterol-Lowering Drug Market Forecast, ($m, AGR%, CAGR%) 2017-2027
  • Table 9.21. Japan Cholesterol-Lowering Drug Market Forecast, ($m, AGR%, CAGR%) 2017-2027
  • Table 9.22. India Cholesterol-Lowering Drug Market Forecast, ($m, AGR%, CAGR%) 2017-2027
  • Table 9.23. Australia Cholesterol-Lowering Drug Market Forecast, ($m, AGR%, CAGR%) 2017-2027
  • Table 9.24. Thailand Cholesterol-Lowering Drug Market Forecast, ($m, AGR%, CAGR%) 2017-2027
  • Table 9.25. Rest of Asia-Pacific Cholesterol-Lowering Drug Market Forecast, ($m, AGR%, CAGR%) 2017-2027
  • Table 9.26. Rest of World Cholesterol-Lowering Drug Market Forecast by Country, ($m, AGR%, CAGR%) 2017-2027
  • Table 9.27. Middle East Cholesterol-Lowering Drug Market Forecast, ($m, AGR%, CAGR%) 2017-2027
  • Table 9.28. Africa Cholesterol-Lowering Drug Market Forecast, ($m, AGR%, CAGR%) 2017-2027
  • Table 9.29. Other Countries Cholesterol-Lowering Drug Market Forecast, ($m, AGR%, CAGR%) 2017-2027
  • Table 11.1. AstraZeneca Plc: Company Overview
  • Table 11.2.. AstraZeneca Plc: Product Portfolio
  • Table 11.3. AstraZeneca Plc: Recent Developments
  • Table 11.4. Merck & Co. Inc.: Company Overview
  • Table 11.5. Merck & Co. Inc.: Product Portfolio
  • Table 11.6. Merck & Co. Inc.: Recent Developments
  • Table 11.7. Pfizer Inc.: Company Overview
  • Table 11.8. Pfizer Inc.: Product Portfolio
  • Table 11.9. Pfizer Inc.: Recent Developments
  • Table 11.10. Kowa Company, Ltd.: Company Overview
  • Table 11.11. Kowa Company, Ltd.: Product Portfolio
  • Table 11.12. Kowa Company, Ltd.: Recent Developments
  • Table 11.13. Daiichi Sankyo Co., Ltd.: Company Overview
  • Table 11.14. AbbVie Inc.: Company Overview
  • Table 11.15. AbbVie Inc.: Product Portfolio
  • Table 11.16. Novartis AG: Company Overview
  • Table 11.17. Novartis AG: Product Portfolio
  • Table 11.18. Novartis AG: Recent Developments
  • Table 11.19. Sanofi S.A.: Company Overview
  • Table 11.20. Sanofi S.A.: Product Portfolio
  • Table 11.21. Sanofi S.A: Recent Developments
  • Table 11.22. Amgen Inc.: Company Overview
  • Table 11.23. Amgen Inc.: Product Portfolio
  • Table 11.24. Amgen Inc.: Recent Developments
  • Table 11.25. Bristol-Myers Squibb: Company Overview
  • Table 11.26. Bristol-Myers Squibb : Product Portfolio

List of Figures

  • Figure 1.1. Global Cholesterol-Lowering Drugs Market Segmentation Overview, 2015
  • Figure 2.1. Chemical Structure of Cholesterol, 2017
  • Figure 3.1. Global Cholesterol-Lowering Drugs Market Segments, by Type ($million) 2017-2027
  • Figure 3.2. Cholesterol-Lowering Drugs Market, by Statins and Fixed-Dose Combination, ($million) 2017-2027
  • Figure 3.3. Cholesterol-Lowering Drugs Market, by Absorption Inhibitors, Ion Exchange Resins, Fibrates and Other Drugs, ($million) 2017-2027
  • Figure 3.4. Cholesterol-Lowering Drugs Market, by PCSK9 Inhibitors, ($million)2017-2027
  • Figure 3.5. Cholesterol-Lowering Drugs Market, by Novel Cholesterol-Lowering Drugs, ($million) 2017-2027
  • Figure 4.1. Global Cholesterol-Lowering Drugs Market Segments, by Type, Market Share (%), 2016
  • Figure 4.2. Global Cholesterol-Lowering Drugs Market Segments, by Type, Forecast ($million) 2017-2027
  • Figure 4.3. Global Statins and Fixed-Dose Combinations for Cholesterol-Lowering Drugs Market Forecast, by Geography, ($million) 2017-2027
  • Figure 4.4. Global Absorption Inhibitors, Ion Exchange Resins, Fibrates and Other for Cholesterol-Lowering Drugs Market Forecast, by Geography, ($million) 2017-2027
  • Figure 4.5. Global PCSK9 Inhibitors for Cholesterol-Lowering Drugs Market Forecast, by Geography, ($million) 2017-2027
  • Figure 4.6. Global Novel Cholesterol-Lowering Drugs for Cholesterol-Lowering Drugs Market Forecast, by Geography, ($million) 2017-2027
  • Figure 5.1. Global Statins and Fixed-Dose Combinations Market by Product ($million) 2017-2027
  • Figure 5.2. Global Statins and Fixed-Dose Combinations Market Share of Products (%), 2016
  • Figure 5.3. Global Crestor Market Forecast ($m) 2017-2027
  • Figure 5.4. Global Lipitor Market Forecast ($m) 2017-2027
  • Figure 5.5. Global Livalo Market Forecast ($m) 2017-2027
  • Figure 5.6. Global Lescol /Lescol XL Market Forecast ($m) 2017-2027
  • Figure 5.7. Global Zocor Market Forecast ($m) 2017-2027
  • Figure 5.8. Global Vytorin Market Forecast ($m) 2017-2027
  • Figure 5.9. Global Caduet Market Forecast ($m) 2017-2027
  • Figure 5.10. Global Others Market of Statins and Fixed-Dose Combinations Segment ($m) 2017-2027
  • Figure 6.1. Global Absorption Inhibitors, Ion Exchange Resins, Fibrates and Other Drugs Market by Product ($million) 2017-2027
  • Figure 6.2. Global Absorption Inhibitors, Ion Exchange Resins, Fibrates and Other Drugs Market Share of Products (%), 2016
  • Figure 6.3. Global Zetia Market Forecast ($m) 2017-2027
  • Figure 6.4. Global Welchol Market Forecast ($m) 2017-2027
  • Figure 6.5. Global Tricor Market Forecast ($m) 2017-2027
  • Figure 6.6. Global Others Market of the Absorption Inhibitors, Ion Exchange Resins, Fibrates and Other Drugs Segment ($m) 2017-2027
  • Figure 7.1. Global PCSK9 Inhibitors Market Share of Products (%), 2016
  • Figure 7.2. Global PCSK9 Inhibitors Market by Product ($million) 2017-2027
  • Figure 7.3. Global Praluent Market Forecast, ($m) 2017-2027
  • Figure 7.4. Global Repatha Market Forecast, ($m) 2017-2027
  • Figure 7.5. Global RN316 Market Forecast, ($m) 2017-2027
  • Figure 7.6. Global Others Market of the PCSK9 Inhibitors Segment, ($m) 2017-2027
  • Figure 8.1. Global Novel Cholesterol-Lowering Drugs, Market Share of Products (%), 2016
  • Figure 8.2. Global Novel Cholesterol-Lowering Drugs Market by Product ($million) 2017-2027
  • Figure 8.3. Global Juxtapid Market Forecast, ($m) 2017-2027
  • Figure 8.4. Global Kynamro Market Forecast, ($m) 2017-2027
  • Figure 8.5. Global MK-089 Market Forecast, ($m) 2017-2027
  • Figure 8.6. Global Other Drugs Market of the Novel Cholesterol-Lowering Drugs Segment, ($m) 2017-2027
  • Figure 9.1. Global Cholesterol-Lowering Drugs Market Forecast by Geography, ($million) 2017-2027
  • Figure 9.2. Global Cholesterol-Lowering Drugs Market by Geography, Market Share (%), 2016
  • Figure 9.3. North America Cholesterol-Lowering Drugs Market Forecast by Country, ($million) 2017-2027
  • Figure 9.4. North America Cholesterol-Lowering Drugs Market by Country, Market Share (%), 2016
  • Figure 9.5. USA Cholesterol-Lowering Drugs Market Forecast ($m) 2017-2027
  • Figure 9.6. The Average Blood Concentration of LDL-C and TC:HDL-C Ratio, Canada, 2012 to 2013
  • Figure 9.7. Canada Cholesterol-Lowering Drugs Market Forecast ($m) 2017-2027
  • Figure 9.8. Mexico Cholesterol-Lowering Drugs Market Forecast ($m) 2017-2027
  • Figure 9.9 South America Cholesterol-Lowering Drugs Market Forecast, by Country ($million) 2017-2027
  • Figure 9.10. South America Cholesterol-Lowering Drugs Market by Country, Market Share (%), 2016
  • Figure 9.11. Brazil Cholesterol-Lowering Drugs Market Forecast ($m) 2017-2027
  • Figure 9.12. Argentina Cholesterol-Lowering Drugs Market Forecast ($m) 2017-2027
  • Figure 9.13. Paraguay Cholesterol-Lowering Drugs Market Forecast ($m) 2017-2027
  • Figure 9.14. Bolivia Cholesterol-Lowering Drugs Market Forecast ($m) 2017-2027
  • Figure 9.15. Rest of South America Cholesterol-Lowering Drugs Market Forecast ($m) 2017-2027
  • Figure 9.16. Europe Cholesterol-Lowering Drugs Market Forecast by Country($million) 2017-2027
  • Figure 9.17. Europe Cholesterol-Lowering Drugs Market by Country, Market Share (%), 2016
  • Figure 9.18. France Cholesterol-Lowering Drugs Market Forecast ($m) 2017-2027
  • Figure 9.19. Germany Cholesterol-Lowering Drugs Market Forecast ($m) 2017-2027
  • Figure 9.20. UK Cholesterol-Lowering Drugs Market Forecast ($m) 2017-2027
  • Figure 9.21. Spain Cholesterol-Lowering Drugs Market Forecast ($m) 2017-2027
  • Figure 9.22. Italy Cholesterol-Lowering Drugs Market Forecast ($m) 2017-2027
  • Figure 9.23. Rest of Europe Cholesterol-Lowering Drugs Market Forecast ($m) 2017-2027
  • Figure 9.24. Asia-Pacific Cholesterol-Lowering Drug Market Forecast by Country, ($million) 2017-2027
  • Figure 9.25. Asia-Pacific Cholesterol-Lowering Drug Market by Country, Market Share (%), 2016
  • Figure 9.26. China Cholesterol-Lowering Drug Market Forecast ($m) 2017-2027
  • Figure 9.27. Japan Cholesterol-Lowering Drug Market Forecast ($m) 2017-2027
  • Figure 9.28. India Cholesterol-Lowering Drug Market Forecast ($m) 2017-2027
  • Figure 9.29. Australia Cholesterol-Lowering Drug Market Forecast ($m) 2017-2027
  • Figure 9.30. Thailand Cholesterol-Lowering Drug Market Forecast ($m) 2017-2027
  • Figure 9.31. Rest of Asia-Pacific Cholesterol-Lowering Drug Market Forecast ($m) 2017-2027
  • Figure 9.32. RoW Cholesterol-Lowering Drug Market Forecast by Country,($million) 2017-2027
  • Figure 9.33. Rest of World Cholesterol-Lowering Drug Market by Country, Market Share (%), 2016
  • Figure 9.34. Middle East Cholesterol-Lowering Drug Market Forecast ($m) 2017-2027
  • Figure 9.35. Africa Cholesterol-Lowering Drug Market Forecast ($m) 2017-2027
  • Figure 9.36. Other Countries Cholesterol-Lowering Drug Market Forecast ($m) 2017-2027
  • Figure 10.1. Porter's Five Forces Analysis of the Cholesterol-Lowering Drugs Market, 2017-2027
  • Figure 11.1. AstraZeneca Plc, Revenue, ($million), 2012-2016
  • Figure 11.2. AstraZeneca Plc, Geographical Presence Share (%), 2016
  • Figure 11.3. Merck & Co. Inc., Revenue, ($million), 2012-2016
  • Figure 11.4. Merck & Co. Inc., Product Segments Share (%), 2016
  • Figure 11.5. Merck & Co. Inc., Geographical Presence Share (%), 2016
  • Figure 11.6. Pfizer Inc., Revenue, ($million), 2012-2016
  • Figure 11.7. Pfizer Inc., Product Segments Share (%), 2016
  • Figure 11.8 Pfizer Inc., Geographical Presence Share (%), 2016
  • Figure 11.9. Daiichi Sankyo Co., Ltd., Revenue, ($million), 2012-2016
  • Figure 11.10. Daiichi Sankyo Co., Ltd., Product Segments Share (%), 2016
  • Figure 11.11. Daiichi Sankyo Co., Ltd., Geographical Presence Share (%), 2016
  • Figure 11.12. AbbVie Inc., Revenue, ($million), 2012-2016
  • Figure 11.13. AbbVie Inc., Product Segments Share (%), 2016
  • Figure 11.14. AbbVie Inc., Geographical Presence Share (%), 2016
  • Figure 11.15. Novartis AG, Revenue, ($million), 2012-2016
  • Figure 11.16. Novartis AG, Product Segments Share (%), 2016
  • Figure 11.17. Novartis AG, Geographical Presence Share (%), 2016
  • Figure 11.18. Sanofi S.A., Revenue, ($million), 2012-2016
  • Figure 11.19. Sanofi S.A., Product Segments Share (%), 2016
  • Figure 11.20. Sanofi S.A., Geographical Presence Share (%), 2016
  • Figure 11.21. Amgen Inc., Revenue, ($million), 2012-2016
  • Figure 11.22. Amgen Inc., Product Segments Share (%), 2016
  • Figure 11.23. Amgen Inc., Geographical Presence Share (%), 2016
  • Figure 11.24. Bristol-Myers Squibb, Revenue, ($million), 2012-2016
  • Figure 11.25. Bristol-Myers Squibb, Product Segments Share (%), 2016
  • Figure 11.26. Bristol-Myers Squibb, Geographical Presence Share (%), 2016
  • Figure 12.1. World Cholesterol-Lowering Drug Market by Region: Revenues ($m), 2017-2027
  • Figure 12.2. World Cholesterol-Lowering Drugs Market Forecastb by Segment: Revenue ($m), 2017-2027
  • Figure 12.3. World Cholesterol-Lowering Drugs Market Driving Factors

Companies Listed

  • Abbott Laboratories
  • AbbVie
  • Accord Healthcare
  • Aegerion Pharmaceuticals
  • Alcon
  • Algorithm SAL
  • Allergan
  • Alynlam Pharmaceuticals
  • Amgen
  • Apotex
  • Astellas Pharma
  • AstraZeneca
  • Aurobindo
  • BASF
  • Bayer
  • Biomarin Pharmaceuticals
  • Blu Caribe
  • Bristol-Myers Squibb
  • Ciba-Geigy
  • Daiichi Sankyo
  • DalCor Pharmaceuticals
  • Dezima Pharma
  • Dr Reddy's Laboratories
  • EGIS Pharmaceuticals
  • Eli Lilly
  • Esperion Therapeutics
  • Eisai
  • Fresenius Medical Care
  • Genzyme Corporation
  • Glenmark
  • Hetero Laboratories
  • Impax Laboratories
  • Intas Pharmaceuticals
  • Isis Pharmaceuticals
  • JW Pharmaceutical
  • Kaneka
  • Kowa
  • Kremers Urban Pharmaceuticals
  • Lek
  • Lupin
  • Merck and Co.
  • Micro Laboratories
  • Miltenyi-Biotec
  • Mylan
  • Novartis
  • Par Pharmaceuticals
  • Pfizer
  • ProEthic Pharmaceuticals
  • ProNova BioPharma
  • Ranbaxy
  • Reckitt Benckiser
  • Recordati
  • Regeneron
  • Roche
  • Sandoz
  • Sanofi
  • Serometrix
  • Shionogi
  • Solvay
  • Sun Pharma
  • Teva
  • Torrent Pharmaceuticals
  • UCB
  • Valeant
  • Warner-Lambert
  • Wockhardt
  • Zydus Cadila

List of Organizations Mentioned in the Report

  • American College of Cardiology
  • American Heart Association
  • Department of Pharmaceuticals (India)
  • European Society of Cardiology
  • National Health Service
  • National Heart, Lung, and Blood Institute
  • United Nations Department of Economic and Social Affairs
  • US Dietary Guidelines Advisory Committee
  • US Food and Drug Administration
  • World Health Organization
Back to Top